Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.

[1]  N. Grishin,et al.  BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.

[2]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[3]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[4]  R. Beyth,et al.  A systematic review of the quality of evidence of ablative therapy for small renal masses. , 2012, The Journal of urology.

[5]  Huanming Yang,et al.  Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma , 2011, Nature Genetics.

[6]  C. Sander,et al.  Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.

[7]  C. Sander,et al.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.

[8]  B. Leibovich,et al.  Treatment of patients with small renal masses: a survey of the American Urological Association. , 2011, The Journal of urology.

[9]  Manuel Hidalgo,et al.  Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer , 2011, Proceedings of the National Academy of Sciences.

[10]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[11]  A. Bowcock,et al.  Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2010, Science.

[12]  Gerben Duns,et al.  Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. , 2010, Cancer research.

[13]  L. Gossage,et al.  Alterations in VHL as potential biomarkers in renal-cell carcinoma , 2010, Nature Reviews Clinical Oncology.

[14]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[15]  Anindya Dutta,et al.  The Deubiquitinating Enzyme BAP1 Regulates Cell Growth via Interaction with HCF-1* , 2009, The Journal of Biological Chemistry.

[16]  T. Roberts,et al.  The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters , 2009, BMC Cancer.

[17]  M. Thompson.  Polybromo-1: the chromatin targeting subunit of the PBAF complex. , 2009, Biochimie.

[18]  J. Ahringer,et al.  Differential chromatin marking of introns and expressed exons by H3K36me3 , 2008, Nature Genetics.

[19]  K. Jones,et al.  The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated histone H3K36 methylation. , 2008, Genes & development.

[20]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[21]  D. Aust,et al.  Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. , 2008, Neoplasia.

[22]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[23]  E. Rankin,et al.  Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. , 2006, Cancer research.

[24]  Craig L. Peterson,et al.  Chromatin Higher Order Folding--Wrapping up Transcription , 2002, Science.

[25]  Charles C Wykoff,et al.  HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. , 2002, Cancer cell.

[26]  Andrew Flaus,et al.  Nucleosome mobilization catalysed by the yeast SWI/SNF complex , 1999, Nature.

[27]  S. Clifford,et al.  Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL‐independent pathway in clear cell renal tumourigenesis , 1998 .

[28]  M. Grunstein.  Histone acetylation in chromatin structure and transcription , 1997, Nature.

[29]  E. Venkatraman,et al.  RESAMPLING PROCEDURES TO COMPARE TWO SURVIVAL DISTRIBUTIONS IN THE PRESENCE OF RIGHT-CENSORED DATA , 1996 .